Treatment of heart failure with preserved ejection fraction


Opinion statement

Heart failure with preserved ejection fraction (HFpEF) is a major public health problem in the United States. However, in contrast to systolic heart failure, there are little data to guide treatment decisions in HFpEF, and no therapies have been shown to improve outcome in these patients. This review explores what is currently known about the pathophysiologic mechanisms causing HFpEF in order to frame appropriate therapeutic targets and better understand the clinical responses commonly observed in patients with HFpEF. Data from published clinical trials are reviewed, and the roles for each class of drug commonly used in practice are examined. Finally, novel therapies and future directions for basic investigation and clinical trials are discussed.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Owan TE, Hodge DO, Herges RM, et al.: Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251–259.PubMedCrossRefGoogle Scholar
  2. 2.
    Bhatia RS, Tu JV, Lee DS, et al.: Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355:260–269.PubMedCrossRefGoogle Scholar
  3. 3.
    Hunt SA, Abraham WT, Chin MH, et al.; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154–e235.PubMedCrossRefGoogle Scholar
  4. 4.
    Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777–781.PubMedCrossRefGoogle Scholar
  5. 5.
    Cleland JG, Tendera M, Adamus J, et al.: The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338–2345.PubMedCrossRefGoogle Scholar
  6. 6.
    Massie BM, Carson PE, McMurray JJ, et al.: Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008 [Epub ahead of print].Google Scholar
  7. 7.
    Borlaug BA, Kass DA: Mechanisms of diastolic dysfunction in heart failure. Trends Cardiovasc Med 2006, 16:273–279.PubMedCrossRefGoogle Scholar
  8. 8.
    Zile MR, Baicu CF, Gaasch WH: Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004, 350:1953–1959.PubMedCrossRefGoogle Scholar
  9. 9.
    Lam CS, Roger VL, Rodeheffer RJ, et al.: Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007, 115:1982–1990.PubMedCrossRefGoogle Scholar
  10. 10.
    Westermann D, Kasner M, Steendijk P, et al.: Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 2008, 117:2051–2060.PubMedCrossRefGoogle Scholar
  11. 11.
    Glantz SA, Parmley WW: Factors which affect the diastolic pressure-volume curve. Circ Res 1978, 42:171–180.PubMedGoogle Scholar
  12. 12.
    Leite-Moreira AF, Correia-Pinto J, Gillebert TC: Afterload induced changes in myocardial relaxation: a mechanism for diastolic dysfunction. Cardiovasc Res 1999, 43:344–353.PubMedCrossRefGoogle Scholar
  13. 13.
    Borlaug BA, Melenovsky V, Redfield MM, et al.: Impact of arterial load and loading sequence on left ventricular tissue velocities in humans. J Am Coll Cardiol 2007, 50:1570–1577.PubMedCrossRefGoogle Scholar
  14. 14.
    Solomon SD, Janardhanan R, Verma A, et al.: Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 2007, 369:2079–2087.PubMedCrossRefGoogle Scholar
  15. 15.
    Kass DA, Midei M, Brinker J, Maughan WL: Influence of coronary occlusion during PTCA on end-systolic and end-diastolic pressure-volume relations in humans. Circulation 1990, 81:447–460.PubMedGoogle Scholar
  16. 16.
    Choudhury L, Gheorghiade M, Bonow RO: Coronary artery disease in patients with heart failure and preserved systolic function. Am J Cardiol 2002, 89:719–722.PubMedCrossRefGoogle Scholar
  17. 17.
    Kramer K, Kirkman P, Kitzman D, Little WC: Flash pulmonary edema: association with hypertension and reoccurrence despite coronary revascularization. Am Heart J 2000, 140:451–455.PubMedCrossRefGoogle Scholar
  18. 18.
    Chen CH, Nakayama M, Nevo E, et al.: Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol 1998, 32:1221–1227.PubMedCrossRefGoogle Scholar
  19. 19.
    Redfield MM, Jacobsen SJ, Borlaug BA, et al.: Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation 2005, 112:2254–2262.PubMedCrossRefGoogle Scholar
  20. 20.
    Borlaug BA, Kass DA: Ventricular-vascular interaction in heart failure. Heart Fail Clin 2008, 4:23–36.PubMedCrossRefGoogle Scholar
  21. 21.
    Klapholz M, Maurer M, Lowe AM, et al.: Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol 2004, 43:1432–1438.PubMedCrossRefGoogle Scholar
  22. 22.
    Gandhi SK, Powers JC, Nomeir AM, et al.: The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001, 344:17–22.PubMedCrossRefGoogle Scholar
  23. 23.
    Kawaguchi M, Hay I, Fetics B, Kass DA: Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003, 107:714–720.PubMedCrossRefGoogle Scholar
  24. 24.
    Hundley WG, Kitzman DW, Morgan TM, et al.: Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol 2001, 38:796–802.PubMedCrossRefGoogle Scholar
  25. 25.
    Warner JG Jr, Metzger DC, Kitzman DW, et al.: Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 1999, 33:1567–1572.PubMedCrossRefGoogle Scholar
  26. 26.
    Little WC, Zile MR, Klein A, et al.: Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction. Am J Cardiol 2006, 98:383–385.PubMedCrossRefGoogle Scholar
  27. 27.
    Shapiro BP, Lam CS, Patel JB, et al.: Acute and chronic ventricular-arterial coupling in systole and diastole. Insights from an elderly hypertensive model. Hypertension 2007, 50:503–511.PubMedCrossRefGoogle Scholar
  28. 28.
    Kitzman DW, Higginbotham MB, Cobb FR, et al.: Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol 1991, 17:1065–1072.PubMedCrossRefGoogle Scholar
  29. 29.
    Borlaug BA, Melenovsky V, Russell SD, et al.: Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006, 114:2138–2147.PubMedCrossRefGoogle Scholar
  30. 30.
    Borlaug BA, Lam CSP, Olson TP, et al.: Cardiovascular reserve function in heart failure with preserved ejection fraction: systolic versus diastolic determinants [abstract]. Circulation 2008, 118:S1022.Google Scholar
  31. 31.
    Brubaker PH, Joo KC, Stewart KP, et al.: Chronotropic incompetence and its contribution to exercise intolerance in older heart failure patients. J Cardiopulm Rehabil 2006, 26:86–89.PubMedCrossRefGoogle Scholar
  32. 32.
    Smith CS, Bottomley PA, Schulman SP, et al.: Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation 2006, 114:1151–1158.PubMedCrossRefGoogle Scholar
  33. 33.
    Yip G, Wang M, Zhang Y, et al.: Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: time for a redefinition? Heart 2002, 87:121–125.PubMedCrossRefGoogle Scholar
  34. 34.
    Yu CM, Lin H, Yang H, et al.: Progression of systolic abnormalities in patients with “isolated” diastolic heart failure and diastolic dysfunction. Circulation 2002, 105:1195–1201.PubMedCrossRefGoogle Scholar
  35. 35.
    Wang J, Khoury DS, Yue Y, et al.: Preserved left ventricular twist and circumferential deformation, but depressed longitudinal and radial deformation in patients with diastolic heart failure. Eur Heart J 2008, 29:1283–1289.PubMedCrossRefGoogle Scholar
  36. 36.
    Baicu CF, Zile MR, Aurigemma GP, Gaasch WH: Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation 2005, 111:2306–2312.PubMedCrossRefGoogle Scholar
  37. 37.
    Melenovsky V, Borlaug BA, Rosen B, et al.: Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/ dysfunction. J Am Coll Cardiol 2007, 49:198–207.PubMedCrossRefGoogle Scholar
  38. 38.
    Aurigemma GP, Zile MR, Gaasch WH: Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation 2006, 113:296–304.PubMedCrossRefGoogle Scholar
  39. 39.
    Borlaug BA, Lam CS, Roger VL, et al.: Myocardial contractile dysfunction in heart failure with preserved ejection fraction [abstract]. Circulation 2008, 118:S1021.CrossRefGoogle Scholar
  40. 40.
    McMurray JJ, Carson PE, Komajda M, et al.: Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008, 10:149–156.PubMedCrossRefGoogle Scholar
  41. 41.
    Aronow WS, Kronzon I: Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993, 71:602–604.PubMedCrossRefGoogle Scholar
  42. 42.
    Little WC, Brucks S: Therapy for diastolic heart failure. Prog Cardiovasc Dis 2005, 47:380–388.PubMedCrossRefGoogle Scholar
  43. 43.
    Flather MD, Shibata MC, Coats AJ, et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005, 26:215–225.PubMedCrossRefGoogle Scholar
  44. 44.
    Ghio S, Magrini G, Serio A, et al.: Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 2006, 27:562–568.PubMedCrossRefGoogle Scholar
  45. 45.
    Chen HH: Heart failure: a state of brain natriuretic peptide deficiency or resistance or both! J Am Coll Cardiol 2007, 49:1089–1091.PubMedCrossRefGoogle Scholar
  46. 46.
    Davis BR, Kostis JB, Simpson LM, et al.: Heart Failure With Preserved and Reduced Left Ventricular Ejection Fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 2008 [Epub ahead of print].Google Scholar
  47. 47.
    Setaro JF, Zaret BL, Schulman DS, et al.: Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990, 66:981–986.PubMedCrossRefGoogle Scholar
  48. 48.
    Ahmed A, Rich MW, Fleg JL, et al.: Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006, 114:397–403.PubMedCrossRefGoogle Scholar
  49. 49.
    Fukuta H, Sane DC, Brucks S, Little WC: Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005, 112:357–363.PubMedCrossRefGoogle Scholar
  50. 50.
    Brucks S, Little WC, Chao T, et al.: Relation of anemia to diastolic heart failure and the effect on outcome. Am J Cardiol 2004, 93:1055–1057.PubMedCrossRefGoogle Scholar
  51. 51.
    Fung JW, Li TS, Choy DK, et al.: Severe obstructive sleep apnea is associated with left ventricular diastolic dysfunction. Chest 2002, 121:422–429.PubMedCrossRefGoogle Scholar
  52. 52.
    van Heerebeek L, Borbely A, Niessen HW, et al.: Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006, 113:1966–1973.PubMedCrossRefGoogle Scholar
  53. 53.
    Sossalla S, Wagner S, Rasenack EC, et al.: Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts—role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 2008, 45:32–43.PubMedCrossRefGoogle Scholar
  54. 54.
    Nagueh SF: Mechanical dyssynchrony in congestive heart failure: diagnostic and therapeutic implications. J Am Coll Cardiol 2008, 51:18–22.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Division of Cardiovascular Diseases, Department of MedicineThe Mayo ClinicRochesterUSA

Personalised recommendations